Patients affected with more severe COVID-19 symptoms showed a hypercoagulation state and disseminated intravascular coagulation, with laboratory tests revealing increased levels of D-dimer, fibrinogen and fibrinogen degradation products, and a prolonged prothrombin time. This evidence concerns the gene F2 and thrombophilia.